Cardiomyopathies and arrhythmias are heart disorders affecting the heart’s mechanical and electrical function, which predispose individuals to heart failure and sudden cardiac death.
Collectively these disorders may affect more than 1 in 200 individuals.
Patients that are tested through the Detect Cardiomyopathy and Arrhythmia program are eligible to receive post-test genetic counseling to help them understand their results.
Genetic testing for cardiomyopathies and arrhythmias is recommended by medical societies, including American College of Cardiology, American Heart Association, Heart Rhythm Society, and Heart Failure Society of America.1-6
This program is available to individuals in the US and Canada suspected of having a familial cardiomyopathy or arrhythmia.
The Detect Cardiomyopathy and Arrhythmia program offers the Invitae Arrhythmia and Cardiomyopathy Comprehensive Panel to test up to 150 genes associated with inherited arrhythmia and cardiomyopathy conditions.
Individuals tested through the Detect Cardiomyopathy and Arrhythmia program are eligible for post-test genetic counseling to help them understand their test results. For assistance with genetic counseling or to schedule an appointment, please click here to learn more.
Clinicians can place an order by following the steps below.
|Place your order||Collect a specimen||Results|
To place a paper-based order, download the paper order form.
To collect a specimen:
To receive results:
If you're a patient and believe you are eligible for this sponsored testing program, you can contact Genome Medical, our third-party telemedicine genetics provider, or work with your healthcare provider.
If the test comes back positive, all of the proband’s blood relatives are eligible for the program using program code CARDIO.
To place an FVT order, download the paper order form.
Confirm a clinical diagnosis and differentiate from other causes
Provide accurate risk stratification
Inform treatment decisions, guide lifestyle modifications, and facilitate genetic counseling
Enable appropriate screening intervals of at-risk family members
Invitae is a genetic information company whose mission is to bring genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae provides clinical-grade, medically actionable genetic information to answer essential health questions across all stages of life.
While third parties and commercial organizations may provide financial support for this program, tests and services are performed by Invitae. Healthcare professionals must confirm that patients meet certain criteria to use the program. Third parties and commercial organizations may receive de-identified patient data from this program, but at no time would they receive patient identifiable information. Third parties and commercial organizations may receive contact information for healthcare professionals who use this program. Genetic testing and counseling are available in the US and Canada. Healthcare professionals and patients who participate in this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any other products or services from Invitae or from third parties or commercial organizations.
1. Towbin JA et al. 2019 HRS Expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019. doi:10.1016/j.hrthm.2019.05.007
2. Al-Khatib SM et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72:e91-e220.
3. Priori SG et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes.. Heart Rhythm. 2013;10:1932-63.
4. Gersh BJ et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary. J Am. Coll Cardiol. 2011;58:2703-38.
5. Ackerman MJ et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm. 2011;8;1308-39.
6. Hershberger, RE et al. Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. J. Card. Fail. 2018;24,281-302.